| Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells K Zafeiropoulou, T Bita, A Polykratis, S Karabina, J Vlachojannis, ... PLoS One 7 (2), e30975, 2012 | 32 | 2012 |
| Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes I Mitroulis, V Papadopoulos, E Lamprianidou, P Mirtschink, K Liapis, ... Blood Cancer Journal 13 (1), 64, 2023 | 2 | 2023 |
| Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5 … V Mpakou, A Spathis, A Bouchla, Z Tsakiraki, F Kontsioti, S Papageorgiou, ... Hematological Oncology 39 (2), 231-242, 2021 | 1 | 2021 |
| Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer K Zafeiropoulou, G Kalampounias, S Alexis, D Anastasopoulos, ... Plos one 19 (2), e0289904, 2024 | | 2024 |
| The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer G Kalampounias, K Zafeiropoulou, T Androutsopoulou, S Alexis, ... bioRxiv, 2024.04. 15.589569, 2024 | | 2024 |
| Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels K Zafeiropoulou, G Kalampounias, S Alexis, T Androutsopoulou, ... Cureus 15 (12), 2023 | | 2023 |
| Investigating the mechanisms underlying Bortezomib resistance K Zafeiropoulou, G Kalampounias, S Alexis, D Anastasopoulos, ... bioRxiv, 2023.07. 29.551081, 2023 | | 2023 |
| PROTEASOME PROTEOLYTIC ACTIVITY IN HEMATOPOIETIC CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES IS INVERSELY ASSOCIATED WITH THEIR OXIDATIVE STRESS K Zafeiropoulou, S Alexis, E Verigou, G Kalampounias, P Katsoris, ... IRB 17955, 20-07, 2020 | | 2020 |
| The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome PT Diamantopoulos, V Pappa, NA Viniou, I Kotsianidis, A Kourakli, ... Blood 134, 5427, 2019 | | 2019 |
| Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients-Data of the Hellenic MDS Study Group V Mpakou, A Spathis, A Bouhla, F Kontsioti, Z Tsakiraki, S Papageorgiou, ... Blood 134, 5403, 2019 | | 2019 |
| The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS—Preliminary Data of the Hellenic MDS Study Group V Mpakou, A Spathis, A Bouhla, K Gkodopoulos, G Stavroulaki, I Glezou, ... Blood 130, 3825, 2017 | | 2017 |
| Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del (5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the … AG Galanopoulos, CK Kontos, A Symeonidis, I Kotsianidis, A Kourakli, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 2979 …, 2017 | | 2017 |
| Primary Resistance to Azacytidine in MDS: Preliminary Data on the Potential Role of HIF-1A Expression–the Hellenic MDS Study Group V Mpakou, A Spathis, F Kontsioti, A Bouhla, K Gontopoulos, G Stavroulaki, ... Leukemia Research 55, S72, 2017 | | 2017 |
| Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group A Galanopoulos, CK Kontos, NA Viniou, I Kotsianidis, V Pappa, A Kourakli, ... Blood, The Journal of the American Society of Hematology 128 (22), 2004-2004, 2016 | | 2016 |
| PRIMARY RESISTANCE TO AZACYTIDINE IN MDS: PRELIMINARY DATA ON THE POTENTIAL ROLE OF HIF-1A EXPRESSION V Bakou, A Spathis, F Kontsioti, D Vasilatou, C Economopoulou, A Bouhla, ... HAEMATOLOGICA 101, 768-769, 2016 | | 2016 |
| Evaluation of 26S proteasome activity in patients with Myelodysplastic syndromes G Kalampounias, T Androutsopoulou, K Zafeiropoulou, P Katsoris, ... | | |
| The development of drug resistance against the proteasome inhibitor Bortezomib; Effects on main signaling pathways, apoptosis and oxidative stress K Zafeiropoulou, G Kalampounias, S Alexis, D Anastasopoulos, ... | | |
